Implant Sciences Receives $2.2 Million Transportation Security Administration Contract
WAKEFIELD, Mass.--(BUSINESS WIRE)--Sept. 7, 2005-- IMPLANT SCIENCES AWARDED ATLANTIC 2 CONTRACT TO DEVELOP "NEXT GENERATION" PASSENGER PORTAL FOR AIRPORTS
Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced the receipt of a $2.2 million contract from the U.S. Transportation Security Administration ("TSA") to develop a new state-of-the-art portal to detect explosives as well as metal weapons on passengers. This contract was awarded pursuant to the TSA's solicitation for competitive proposals for Project ATLANTIC-2.
Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, "We are gratified at the TSA's decision to award Implant Sciences this important contract to develop a "next generation" passenger portal that could improve security at personnel entry points in locations such as airports. We believe our advanced explosives detection technology, in combination with metal detection capability, could provide the TSA and the traveling public with the best performing, least obtrusive, portal technology in a single walk-through device. Our team of engineers and technicians has already begun the hard work necessary to make this advanced portal a reality."
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives. In addition, to its other cancer treatment products the Company recently received an FDA 510k approval for its new radioactive source for the use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com.
Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission.